Suchergebnisse - "Li, Yilin"

PubPharm (8)

1

Toxicity and therapy outcome associations in LIG3, SLCO1B3, ABCB1, OPRM1 and GSTP1 in high-grade serous ovarian cancer

enthalten in: Basic & clinical pharmacology & toxicology | 2023

von Deng, F. | Laasik, M. | Salminen, L. | +7

2

FOXD3 confers chemo-sensitivity in ovarian cancer through a miR-335/DAAM1/myosin II axis-dependent mechanism

enthalten in: Journal of ovarian research | 2023

von Wang, S. | Ma, Y. | Hu, Y. | +4

3

Effectiveness and safety of weekly therapy versus 3-weekly therapy of paclitaxel plus carboplatin in women with ovarian cancer : a protocol of systematic review and meta-analysis

enthalten in: BMJ open | 2022

von Qiu, W. | Fu, Y. | Dang, Y. | +6

4

Dynamic monitoring of circulating tumour cells to evaluate therapeutic efficacy in advanced gastric cancer

enthalten in: British journal of cancer | 2016

von Li, Y. | Gong, J. | Zhang, Q. | +5

5

Serum levels of TUBB3 correlate with clinical outcome in Chinese patients with advanced gastric cancer receiving first-line paclitaxel plus capecitabine

enthalten in: Medical oncology (Northwood, London, England) | 2012

von Yu, J. | Gao, J. | Lu, Z. | +2

6

Serum levels of TUBB3 correlate with clinical outcome in Chinese patients with advanced gastric cancer receiving first-line paclitaxel plus capecitabine

enthalten in: Medical oncology | 2012

von Yu, J. | Gao, J. | Lu, Z. | +2

7

Serum levels of TUBB3 correlate with clinical outcome in Chinese patients with advanced gastric cancer receiving first-line paclitaxel plus capecitabine

enthalten in: Medical oncology | 2012

von Yu, J. | Gao, J. | Lu, Z. | +2

8

Serum levels of TUBB3 correlate with clinical outcome in Chinese patients with advanced gastric cancer receiving first-line paclitaxel plus capecitabine

enthalten in: Medical oncology | 2012

von Yu, J. | Gao, J. | Lu, Z. | +2

1
[1]